Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $115,835.40 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 6,774 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $115,835.40. Following the transaction, the insider owned 53,029 shares in the company, valued at approximately $906,795.90. This represents a 11.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

TAK stock opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90. The business has a 50-day moving average price of $16.57 and a 200 day moving average price of $17.14. The company has a market capitalization of $56.53 billion, a P/E ratio of 51.89 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, equities research analysts forecast that Takeda Pharmaceutical Co. will post 0.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on TAK shares. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

Several hedge funds have recently modified their holdings of the company. Private Trust Co. NA boosted its holdings in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after acquiring an additional 1,684 shares in the last quarter. SHP Wealth Management acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $42,000. Caitong International Asset Management Co. Ltd grew its holdings in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after purchasing an additional 1,292 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.